GPR109A agonist

This page covers all GPR109A agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting GPR109A.

Targets

GPR109A

Phase 3 pipeline (1)

• MK0524A, /Duration of Treatment : 4 Weeks · Merck Sharp & Dohme LLC · Cardiovascular
  MK0524A is a niacin receptor agonist that activates GPR109A to raise HDL cholesterol and lower triglycerides.